Latest Oncology News

Botensilimab/Balstilimab Combo Produces Deep Responses in Microsatellite Stable CRC

Botensilimab/Balstilimab Combo Produces Deep Responses in Microsatellite Stable CRC

June 29th 2022

Kristi Rosa

The combination of botensilimab and balstilimab elicited deep objective responses with evidence of durability and encouraging tolerability in heavily pretreated patients with microsatellite stable, metastatic colorectal cancer.

Atezolizumab Does Not Improve pCR in HER2-Positive Early Breast Cancer

Atezolizumab Does Not Improve pCR in HER2-Positive Early Breast Cancer

June 29th 2022

Jason Harris

Adding atezolizumab to neoadjuvant standard of care therapy for HER2-positive early breast cancer did not result in a better pathologic complete response compared with placebo, according to findings from the phase 3 IMpassion050 trial.

Second-Line RGX-202-01 Plus FOLFIRI/Bevacizumab Shows Early Efficacy, Safety in KRAS-Mutant CRC

Second-Line RGX-202-01 Plus FOLFIRI/Bevacizumab Shows Early Efficacy, Safety in KRAS-Mutant CRC

June 29th 2022

Kristi Rosa

A second-line combination regimen comprised of RGX-202-01, FOLFIRI and bevacizumab demonstrated an encouraging efficacy signal and a favorable toxicity profile in patients with KRAS-mutant colorectal cancer.

FDA Grants Breakthrough Therapy Designation to Talquetamab for Relapsed/Refractory Myeloma

FDA Grants Breakthrough Therapy Designation to Talquetamab for Relapsed/Refractory Myeloma

June 29th 2022

Kristi Rosa

The FDA has granted a breakthrough therapy designation to talquetamab for use as a potential therapeutic option in patients with relapsed or refractory multiple myeloma who received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.

Socazolimab Shows Early Efficacy, Safety in Recurrent or Metastatic Cervical Cancer

Socazolimab Shows Early Efficacy, Safety in Recurrent or Metastatic Cervical Cancer

June 29th 2022

Chris Ryan

Socazolimab produced encouraging response rates with an acceptable safety profile in patients with recurrent or metastatic cervical cancer, irrespective of PD-L1 status, according to findings from the dose-expansion portion of a phase 1 trial.

Latest Oncology Videos

All Oncology News

Stadtmauer Spotlights the Explosion of BCMA-Directed Therapies in Multiple Myeloma

January 14th 2021

Erica DiNapoli

Edward A. Stadtmauer, MD, highlights the emergence of several BCMA-directed therapies, such as monoclonal antibodies, antibody-drug conjugates, and bispecific antibodies, and how outcomes for patients with multiple myeloma have improved significantly.

TKIs Set the Stage for Treatment in HER2-Mutant Lung Cancer, But May Be Eclipsed by ADCs

January 14th 2021

Caroline Seymour

Lecia V. Sequist, MD, MPH, discusses some of the advances that bore out in 2020 in HER2-mutant lung cancer and previewed anticipated developments in 2021.

INN Melphalan Flufenamide–DEX for Older Patients With RRMM

January 14th 2021

Paul Richardson, MD, Dana-Farber Cancer Institute

RRMM & High-Risk Cytogenetics: INN Melphalan Flufenamide/DEX

January 14th 2021

Paul Richardson, MD, Dana-Farber Cancer Institute

RRMM: INN Melphalan Flufenamide/DEX and Extramedullary Disease

January 14th 2021

Paul Richardson, MD, Dana-Farber Cancer Institute

HORIZON vs MAMMOTH Explored in R/R Multiple Myeloma

January 14th 2021

Paul Richardson, MD, Dana-Farber Cancer Institute

INN Melphalan Flufenamide in Triple-Class Refractory/Relapsed MM

January 14th 2021

Paul Richardson, MD, Dana-Farber Cancer Institute

Treatment Advances in Triple-Class Refractory/Relapsed Myeloma

January 14th 2021

Paul Richardson, MD, Dana-Farber Cancer Institute

Dr. Lees on the Utility of Genetic Testing in Ovarian Cancer

January 14th 2021

Brittany F. Lees, MD

Brittany F. Lees, MD, discusses the utility of genetic and genomic testing in ovarian cancer.

Rapid Readouts: Results from the Phase 3 ANDROMEDA Study

January 14th 2021

Raymond L. Comenzo, MD, Tufts Medical Center

Dr. Kelly on the Safety Profile of Adjuvant Nivolumab in Resected Esophageal/GEJ Cancer

January 14th 2021

Ronan J. Kelly, MD, MBA

Ronan J. Kelly, MD, MBA, discusses the safety profile of adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer.

Dr. Sun on the KEYNOTE-062 Design in Advanced Gastric/GEJ Cancer

January 14th 2021

Weijing Sun, MD

Weijing Sun, MD, FACP, discusses the design of the KEYNOTE-062 trial in advanced gastric/gastroesophageal junction cancer.

Dr. Berlin on Unmet Needs in Pancreatic Cancer

January 14th 2021

Jordan D. Berlin, MD

Jordan D. Berlin, MD, discusses unmet needs in pancreatic cancer.

Dr. Konecny on the Survival Benefit Achieved With Maintenance PARP Inhibitors in Ovarian Cancer

January 14th 2021

Gottfried E. Konecny, MD

Gottfried E. Konecny, MD, discusses the impact of maintenance PARP inhibitors on survival in patients with ovarian cancer.

Dr. Zakhour on Clinical Trials Examining Frontline Maintenance PARP Inhibitors in Ovarian Cancer

January 14th 2021

Mae Zakhour, MD

Mae Zakhour, MD, discusses clinical trials that evaluated frontline maintenance PARP inhibitors in patients with ovarian cancer.

See All News